Using a state-of-the-art rigorous proteomic approach and validation in a completely independent cohort, we identified and positively validated six promising CSF biomarker candidates for DLB, namely VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N (proSAAS). Here, NPTX2 is linked to Lewy body dementia.